Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 32Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Neoplasm Metastasis 3Carcinoma, Ovarian Epithelial 3Pancreatic Neoplasms 2Lung Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Sarcoma 1Recurrent Uterine Corpus Sarcoma 1Recurrence 1Pain 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Liver Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Endometrial Adenocarcinoma 1

Interventions

Taxes 5Paclitaxel 5Carboplatin 4Immunoglobulin G 2Disulfides 2Cisplatin 2Bevacizumab 2temsirolimus 1pegfilgrastim 1nintedanib 1ixabepilone 1cediranib 1brivanib 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1Metformin 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Epothilones 1Doxorubicin 1Brachytherapy 1AZD 6244 1ALK1-Fc fusion protein, human 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Endometrial Adenocarcinoma × ixabepilone × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡